fda-and-biotech News
Ionis Hits 52-Week High as Hepatitis B Drug Succeeds in Phase 3
Shares surge after the GSK-partnered drug, bepirovirsen, demonstrates a functional cure, paving the way for regulatory filings in early 2026.
Merck Challenges Rivals with Keytruda Combo in Lung Cancer Trial
Initiates Phase 3 study for oral KRAS inhibitor calderasib, aiming to secure a first-line, chemo-free therapy in a lucrative cancer market.
Zymeworks Hits 52-Week High on 'Unprecedented' Cancer Drug Results
Phase 3 data shows its zanidatamab therapy extends survival past two years in stomach cancer, prompting partner Jazz Pharma to ready FDA submission.
Eli Lilly Bets on Oral Obesity Drug in $1.3B Nimbus Pact
Deal reinforces Lilly's strategy to dominate the next wave of metabolic disease therapies, expanding its pipeline beyond injectable treatments.
Instil Bio Stock Collapses After Halting New Cancer Drug Program
Shares plummeted nearly 50% after the company's subsidiary ended development of its AXN-2510 asset, marking another major pipeline setback for the biotech firm.
Lilly Bets Big on Oral Obesity Drug in New $1.3B Nimbus Pact
The deal aims to crack the next frontier in weight-loss treatment, expanding Lilly's arsenal beyond its blockbuster injectable drugs Zepbound and Mounjaro.
Bright Minds Stock Soars 23% on Positive Epilepsy Drug Trial Data
Phase 2 study shows significant seizure reduction in rare epilepsy syndromes, setting the stage for pivotal trials and hitting a new 52-week high.
Alumis Stock More Than Doubles on Positive Psoriasis Drug Trial Results
The biotech's oral drug, envudeucitinib, demonstrated high rates of skin clearance in Phase 3 studies, positioning it as a potential best-in-class competitor to established treatments.